Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Eisai and Biogen announced FDA approval for LEQEMBI’s once every four weeks maintenance dosing for Alzheimer’s disease treatment.